NeuroSense Therapeutics Reports Mid-Year Financials

Neurosense Therapeutics Ltd. (NRSN) has released an update.

NeuroSense Therapeutics Ltd. has reported a decrease in total assets from $3,185,000 to $1,841,000 within the first half of 2024, reflecting a significant drop in cash and cash equivalents. The company’s net loss widened to $6,261,000 for the six months ended June 30, 2024, compared to the same period in the previous year. Despite a challenging period, NeuroSense continued to raise capital through the issuance of shares, bringing in a net amount of $4,209,000.

For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.